Diana Moore replaces Conrad Mir at Advaxis
This article was originally published in Scrip
Conrad Mir, executive director of business development at Advaxis, a biotechnology company developing immunotherapies for cancer and infectious diseases, has left the company to pursue other interests, and has been replaced by Diana Moore who has been appointed director of investor relations and business development. Ms Moore has been at Advaxis for two years in various roles.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.